EA200500609A1 - Ассоциация лиганда рецепторов, активированных пролифератором пероксисом, и антиоксидантного агента и фармацевтические композиции, которые их содержат - Google Patents

Ассоциация лиганда рецепторов, активированных пролифератором пероксисом, и антиоксидантного агента и фармацевтические композиции, которые их содержат

Info

Publication number
EA200500609A1
EA200500609A1 EA200500609A EA200500609A EA200500609A1 EA 200500609 A1 EA200500609 A1 EA 200500609A1 EA 200500609 A EA200500609 A EA 200500609A EA 200500609 A EA200500609 A EA 200500609A EA 200500609 A1 EA200500609 A1 EA 200500609A1
Authority
EA
Eurasian Patent Office
Prior art keywords
association
proliferator
peroxis
ligand
contained
Prior art date
Application number
EA200500609A
Other languages
English (en)
Other versions
EA010353B1 (ru
Inventor
Луи Кастейя
Люк Пенико
Катрин Дакке
Пьер Ренар
Original Assignee
Ле Лаборатуар Сервье
Сентр Насиональ Де Ля Решерш Сьентифик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье, Сентр Насиональ Де Ля Решерш Сьентифик filed Critical Ле Лаборатуар Сервье
Publication of EA200500609A1 publication Critical patent/EA200500609A1/ru
Publication of EA010353B1 publication Critical patent/EA010353B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ассоциация, включающая один или более лигандов рецепторов, активированных пролифератором пероксисом, и антиоксидантный агент. Лекарственные средства.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500609A 2002-10-11 2003-10-10 Ассоциация росиглитазона или его соли с коэнзимом q, ее применение и фармацевтические композиции, которые содержат эту ассоциацию EA010353B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212646A FR2845602B1 (fr) 2002-10-11 2002-10-11 Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
PCT/FR2003/002986 WO2004032967A1 (fr) 2002-10-11 2003-10-10 Association entre un ligand des ppar et un agent antioxydant et utilisation dans le traitement de l'obesite

Publications (2)

Publication Number Publication Date
EA200500609A1 true EA200500609A1 (ru) 2005-10-27
EA010353B1 EA010353B1 (ru) 2008-08-29

Family

ID=32039639

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500609A EA010353B1 (ru) 2002-10-11 2003-10-10 Ассоциация росиглитазона или его соли с коэнзимом q, ее применение и фармацевтические композиции, которые содержат эту ассоциацию

Country Status (20)

Country Link
US (1) US20060002911A1 (ru)
EP (2) EP1815858A3 (ru)
JP (1) JP2006505548A (ru)
KR (1) KR20050072759A (ru)
CN (1) CN100571776C (ru)
AR (1) AR041579A1 (ru)
AU (1) AU2003299772C1 (ru)
BR (1) BR0314539A (ru)
CA (1) CA2501964A1 (ru)
EA (1) EA010353B1 (ru)
FR (1) FR2845602B1 (ru)
GE (1) GEP20084462B (ru)
MA (1) MA27402A1 (ru)
MX (1) MXPA05003893A (ru)
MY (1) MY140562A (ru)
NO (1) NO20052231L (ru)
NZ (2) NZ566708A (ru)
PL (1) PL376045A1 (ru)
UA (1) UA81132C2 (ru)
WO (1) WO2004032967A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545799A (ja) * 2005-06-10 2008-12-18 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ 脂肪組織における末梢時計の調節
JP4863204B2 (ja) * 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100022442A1 (en) * 2008-07-25 2010-01-28 Ambryx Biotechnology, Inc. Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels
EA201101519A1 (ru) * 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
US10530115B2 (en) * 2014-10-02 2020-01-07 ETH Zürich Pulsed laser

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
DE10044805A1 (de) * 2000-09-11 2002-04-04 Martin Klingenberg Verwendung von Coenzym Q zur Regulierung der Funktion der Entkopplerproteine
CZ301282B6 (cs) * 2000-10-26 2009-12-30 Fournier Laboratories Ireland Limited Farmaceutická smes fenofibrátu a koenzymu Q10 pro lécení endotelové dysfunkce
EP1357908A4 (en) * 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
CA2437118A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
BR0207227A (pt) * 2001-02-15 2004-02-10 Pfizer Prod Inc Compostos receptores ativados proliferadores ppar

Also Published As

Publication number Publication date
NO20052231L (no) 2005-05-06
JP2006505548A (ja) 2006-02-16
WO2004032967A1 (fr) 2004-04-22
CN100571776C (zh) 2009-12-23
AU2003299772B2 (en) 2009-03-12
NZ539331A (en) 2008-08-29
EP1815858A2 (fr) 2007-08-08
CA2501964A1 (fr) 2004-04-22
WO2004032967A8 (fr) 2005-05-06
MA27402A1 (fr) 2005-06-01
US20060002911A1 (en) 2006-01-05
UA81132C2 (en) 2007-12-10
CN1703244A (zh) 2005-11-30
AU2003299772A1 (en) 2004-05-04
EA010353B1 (ru) 2008-08-29
MY140562A (en) 2009-12-31
GEP20084462B (en) 2008-08-25
AR041579A1 (es) 2005-05-18
MXPA05003893A (es) 2005-08-03
EP1815858A3 (fr) 2007-12-19
EP1549348A1 (fr) 2005-07-06
NZ566708A (en) 2009-11-27
FR2845602A1 (fr) 2004-04-16
KR20050072759A (ko) 2005-07-12
AU2003299772C1 (en) 2009-08-27
FR2845602B1 (fr) 2005-07-08
PL376045A1 (en) 2005-12-12
BR0314539A (pt) 2005-07-26

Similar Documents

Publication Publication Date Title
EA200501586A1 (ru) Фармацевтические продукты
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
EA200401169A1 (ru) Аминометилзамещенные тетрациклиновые соединения
EA200401526A1 (ru) Новые соединения и их применение
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
MX2007005205A (es) Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
EP1591112A4 (en) INHIBITOR OF BREAST CANCER RESISTANT PROTEIN
RS54614B1 (en) Acetone solvate dimethoxy docetaxel and procedure for its production
SE0301700D0 (sv) Novel compounds
NO20063393L (no) Farmasoytiske preparater
RS51694B (en) NEW PERINDOPRIL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THERE
EA200001039A1 (ru) Кальцилитические соединения
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200500609A1 (ru) Ассоциация лиганда рецепторов, активированных пролифератором пероксисом, и антиоксидантного агента и фармацевтические композиции, которые их содержат
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
SV2006002238A (es) Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh
EA200401331A1 (ru) Фармацевтическая препаративная форма, включающая мелатонин
ATE529432T1 (de) Azazyklosteroid als ligande der histamin-3 rezeptoren
ATE409040T1 (de) Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU